Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia

Drugs

Volumn 67, Issue 6, 2007, Pages 903-914

  Wood, G Christopher ^a   Swanson, Joseph M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM; CARBENICILLIN; CEFOTAXIME; CEFTAZIDIME; COLISTIN; GENTAMICIN; PAROMOMYCIN; PLACEBO; POLYMYXIN; RIFAMPICIN; SALBUTAMOL; SISOMICIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ARTIFICIAL VENTILATION; BRONCHOSPASM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; HOSPITAL INFECTION; HUMAN; HYPOTENSION; LUNG DISEASE; MONOTHERAPY; NEBULIZER; NEPHROTOXICITY; OTOTOXICITY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; TASTE DISORDER; TREATMENT FAILURE; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 34247186991     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767060-00006     Document Type: Review

References (72)

1. American Thoracic Society/Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
2. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; 25: CD004197
3. Wood GC, Boucher BA, Croce MA, et al. Aerosolized ceftazidime for the prevention of ventilator-associated pneumonia and its effects on the inflammatory response in critically ill trauma patients. Pharmacotherapy 2002; 22: 972-82
4. Croce MA, Tolley EA, Fabian TC. A formula for prediction of posttraumatic pneumonia based on early anatomic and physiologic parameters. J Trauma 2003; 54: 724-30
5. Kollef MH. Selective digestive decontamination should not be routinely employed. Chest 2003; 123 (5 Suppl.): 464-8S
6. Klastersky J, Huysmans E, Weerts D, et al. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 1974; 65: 650-4
7. Klastersky J, Hensgens C, Noterman J, et al. Endotracheal antibiotics for the prevention of tracheobronchial infection in tracheotomized unconscious patients: a comparative study of gentamicin and aminosidin-polymyxin B combination. Chest 1975; 68: 302-6
8. Levine BA, Petroff PA, Slade CL, et al. Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. J Trauma 1978; 18: 188-93
9. Vogel F, Werner H, Exner M, et al. Prophylaxis and treatment of respiratory tract infection in ventilated patients by endotracheal administration of aminoglycosides [abstract; in German]. Dtsch Med Wochenschr 1981; 106: 898-903
10. Greenfield S, Teres D, Bushnell LS, et al. Prevention of Gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis I: effect on the colonization pattern of the upper respiratory tract of seriously ill patients. J Clin Invest 1973; 52: 2935-40
11. Klick JM, du Moulin GC, Hedley-Whyte J, et al. Prevention of Gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis: effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 1975; 55: 514-9
12. Feeley TW, du Moulin GC, Hedley-Whyte J, et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293: 471-5
13. Lode H, Hoffken G, Kemmerich B, et al. Systemic and endotracheal antibiotic prophylaxis of nosocomial pneumonia in ICU. Intensive Care Med 1992; 18 Suppl. 1: S24-7
14. Rathgeber J, Zielmann S, Panzer C, et al. Prevention of pneumonia by endotracheal micronebulization of tobramycin [abstract; in German]. Anasthesiol Intensivemed Notfallmed Schmerzther 1993; 28: 23-9
15. Rouby JJ, Poete P, de Lassale M, et al. Prevention of Gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Intensive Care Med 1994; 20: 187-92
16. Brown RB, Phillips D, Barker MJ, et al. Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. Am J Infection Control 1989; 17: 121-5
17. LeConte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147: 1279-82
18. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57
19. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94
20. Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. BMJ 1967; 2: 543-5
21. Pines A, Raafat H, Siddiqui GM, et al. Treatment of severe Pseudomonas infections of the bronchi. BMJ 1970; 1: 663-5
22. Klastersky J, Geuning C, Mouawad E, et al. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972; 61: 117-20
23. Klastersky J, Carpentier-Meunier F, Kahan-Coppens L, et al. Endotracheally administered antibiotics for Gram-negative bronchopneumonia. Chest 1979; 75: 586-91
24. Sorensen VJ, Horst HM, Obeid FN, et al. Endotracheal aminoglycosides in Gram-negative pneumonia: a preliminary report. Am Surgeon 1986; 52: 391-4
25. Stillwell PC, Kearns GL, Jacobs RF. Endotracheal tobramycin in Gram-negative pneumonitis. Drug Intell Clin Pharm 1988; 22: 577-81
26. McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther Drug Monit 1989; 11: 692-5
27. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162: 328-30
28. Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54: 566-9
29. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53-9
30. Horianopoulou M, Lambropoulos S, Papafragas E, et al. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 2005; 17: 536-8
31. Kwa ALH, Loh CS, Low JGH, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41: 754-7
32. Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug resistant Gram-negative infections. Am J Health-Syst Pharm 2005; 62: 39-47
33. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-8
34. Stoutenbeek CP, van Saene HKF, Miranda DR, et al. Nosocomial Gram-negative pneumonia in critically ill patients: a 3-year experience with a novel therapeutic regimen. Intensive Care Med 1986; 12: 419-23
35. Gradon JD, Wu EH, Lutwick LI. Aerosolized vancomycin therapy facilitating nursing home placement. Ann Pharmacother 1992; 26: 209-10
36. Solis A, Brown D, Hughes J, et al. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 2003; 36: 189-95
37. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95
38. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41
39. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20: 166-81
40. Lifschitz MI, Denning CR. Safety of kanamycin aerosol. Clin Pharmacol Ther 1970; 12: 91-5
41. Dickie KJ, de Groot WJ. Ventilatory effects of aerosolized kanamycin and polymyxin. Chest 1973; 63: 694-7
42. Marschke G, Sarauw A. Danger of polymyxin B inhalation [letter]. Ann Int Med 1971; 74: 296-7
43. Dodd MI, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997; 52: 656-8
44. Dally MB, Kurrle S, Breslin ABX. Ventilatory effects of aerosol gentamicin. Thorax 1978; 33: 54-6
45. Hakaem HA, Almohaizeie AM. Hypotension following treatment with aerosolized colistin in a patient with multidrug-resistant Pseudomonas aeruginosa. Ann Pharmacother 2006; 40: 1677-80
46. Eschenbacher WL, Boushey HA, Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, and absence of a premeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211-5
47. Godden DJ, Borland C, Lowry R, et al. Chemical specificity of coughing in man. Clin Sci 1986; 70: 301-6
48. Lowry RH, Wood AM, Higenbottam TW. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci 1988; 74: 373-6
49. Chua HL, Collis GG, LeSouef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 1990; 3: 1114-6
50. Desager KN, Van Bever HP, Stevens WJ. Osmolality and pH of anti-asthmatic drug solutions. Agents Actions 1990; 31: 225-8
51. Downes H, Hirshman CA. Calcium chelators increase airway responsiveness. J Appl Physiol 1985; 59: 92-5
52. O'Doherty MJ, Thomas SHL, Page CJ, et al. Delivery of a nebulized aerosol to a lung model during mechanical ventilation: effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 1992; 146: 383-8
53. O'Riordan TG, Greco MJ, Perry RJ, et al. Nebulizer function during mechanical ventilation. Am Rev Respir Dis 1992; 145: 1117-22
54. O'Doherty MJ, Thomas SHL. Nebuliser therapy in the intensive care unit. Thorax 1997; 52 Suppl. 2: S56-9
55. Hess D, Horney D, Snyder T. Medication-delivery performance of eight small-volume, hand-held nebulizers: effects of diluent volume, gas flowrate, and nebulizer model. Respir Care 1989; 34: 717-23
56. Weber A, Morlin G, Cohen M, et al. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997; 23: 249-60
57. Hughes JM, Saez J. Effects of nebulizer mode and position in a mechanical ventilator circuit on dose efficiency. Respir Care 1987; 32: 1131-5
58. Kim CS, Eldrige MA, Sackner MA. Delivery efficiency of aerosols in intubated subjects [abstract]. Am Rev Respir Dis 1984; 129: A110
59. Fuller HD, Dolovich MB, Chambers C, et al. Aerosol delivery during mechanical ventilation: a predictive in-vitro lung model. J Aerosol Med 1992; 5: 251-9
60. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998; 26: 31-9
61. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136: 1445-9
62. Lake KB, Van Dyke JJ, Rumsfeld JA. Combined topical pulmonary and systemic gentamicin: the question of safety. Chest 1975; 68: 62-4
63. Cooney GF, Lum BL, Tomaselli M, et al. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994; 34: 255-9
64. Touw DJ, Jacobs FAH, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 184-7
65. Trnovec T, Durisova M, Bezek S, et al. Pharmacokinetics of gentamicin administered intratracheally or as an inhalation aerosol to guinea pigs. Drug Metab Dispos 1984; 12: 641-4
66. Vogel F, Exner M, von Lilienfeld-Toal H, et al. Serum gentamicin concentrations during intratracheal administration. Klin Wochenschr 1984; 62: 394-8
67. Badia JR, Soy D, Adrover M, et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004; 54: 508-14
68. MacIntyre NR, Silver RM, Miller CW, et al. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985; 13: 81-4
69. Miller DD, Amin MM, Palmer LB, et al. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003; 168: 1205-9
70. Diot P, Gagnadoux F, Martin C, et al. Nebulization and anti-Pseudomonas aeruginosa activity of colistin. Eur Respir J 1997; 10: 1995-8
71. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1: 67-86
72. Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006; 23: 931-40